^
    Apply
    Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers (NCT03195699)
    Phase 1
    Tvardi Therapeutics, Incorporated
    Active, not recruiting
    Last update posted :
    04/10/2024
    Initiation :
    11/15/2017
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    PD-1
    |
    PD-L1 expression
    |
    TTI-101 oral